

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 22 EMBASE is now updated on a daily basis  
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL  
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT  
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected  
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records  
NEWS 17 MAY 11 KOREAPAT updates resume  
NEWS 18 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 19 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2  
NEWS 20 MAY 30 The F-Term thesaurus is now available in CA/CAplus  
NEWS 21 JUN 02 The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS JUNE 16 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 23 MAY 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:10:04 ON 19 JUN 2006

=> file pctfull  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'PCTFULL' ENTERED AT 16:10:19 ON 19 JUN 2006  
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 13 JUN 2006 <20060613/UP>  
MOST RECENT UPDATE WEEK: 200623 <200623/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.  
SEE  
[<http://www.stn-international.de/stndatabases/details/ipc-reform.html>>>](http://www.stn-international.de/stndatabases/details/ipc-reform.html)

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE  
(last updated April 10, 2006) <<<

=> s WO0071135/pn  
L1 0 WO0071135/PN  
(WO71135/PN)

=> s WO 0071135/pn  
L2 0 WO 0071135/PN  
(WO71135/PN)

=> s WO200071135/pn  
L3 1 WO200071135/PN  
(WO2000071135/PN)

=> s enhance? or synerg? or additi?  
279226 ENHANCE?  
36077 SYNERG?  
711063 ADDITI?  
L4 734288 ENHANCE? OR SYNERG? OR ADDITI?

=> s 14 and 13  
L5 1 L4 AND L3

=> d ibib kwic

L5 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2000071135 PCTFULL ED 20020515  
TITLE (ENGLISH): ANTI-TUMOR COMPRISING BOROPROLINE COMPOUNDS  
TITLE (FRENCH): AGENTS ANTI-TUMORALES CONTENANT DES COMPOSES DE  
BOROPROLINE  
INVENTOR(S): WALLNER, Barbara, P.;  
MILLER, Glenn  
PATENT ASSIGNEE(S): POINT THERAPEUTICS, INC.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000071135	A1	20001130

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ  
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN  
MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR  
TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ

TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK  
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM  
GA GN GW ML MR NE SN TD TG  
APPLICATION INFO.: WO 2000-US14505 A 20000525  
PRIORITY INFO.: US 1999-60/135,861 19990525  
PI WO 2000071135 A1 20001130

DETD . . . rate of division  
io and iTi. some cases uncontrolled growth. One examplc o 'i a  
proliferative cell disorder is a  
tumor. In addition to posing a serious health risk in and of  
themselves, primary malignant  
tumors are particularly problematic given their tendency to invade. . .

In addition to agents of Formula 11, other agents useful in  
the invention include those  
in which the proline residue in Formula 11. . .

In addition, agents can be selected that are effective as  
anti-proliferative agents or as  
anti-angiogenic agents butiare relatively ineffective as hemopoietic  
cell stimulatory. . .

In addition, agents of Formula I can be selected that are  
effective as anti-proliferative  
agents but are relatively ineffective as hemopoietic'cell stimulatory.

1,3-butane diol. Among the  
acceptable vehicles and solvents that may be employed are water,  
Ringer's solution, and  
isotonic sodium chloride solution. In addition, sterile, fixed  
oils are conventionally employed  
as a solvent or suspending medium. For this purpose, any bland fixed oil  
may be employed  
including synthetic mono- or di-glycerides. In addition, fatty  
acids such as oleic acid may be  
used in the preparation of injectables. Carrier formulations suitable  
for oral, subcutaneous,  
intravenous, intramuscular,. . .

vehicles include fluid and nutrient replenishers, electrolyte  
replenishers  
(such as those based on Ringer's dextrose), and the like. Preservatives  
and other additives  
may also be present such as, for example, antimicrobials, anti-oxidants,  
chelating compounds,  
and inert gases and the like. The pharmaceutical compositions may. . .

poly(valeric acid), and poly(lactide-cocaprolactone), and natural  
polymers such as  
alginate and other polysaccharides including dextran and cellulose,  
collagen, chemical  
derivatives thereof (substitutions, additions of chemical  
groups, for example, alkyl, alkylene,  
hydroxylations, oxidations, and other modifications routinely made by  
those skilled in the  
art), albumin and. . .

active component permeates at a  
controlled rate from a polymer such as described in U.S. Patent Nos.  
3,854,480, 5,133,974  
and 5,407,686. In addition, pump-based hardware delivery  
systems can be used, some of

which are adapted for implantation.

levels of IL-6 are secreted from bone marrow stromal cells of D+ and D- rats. Moreover, IL-6 levels for both strains were

enhanced by the addition of PT Bone marrow stromal cells were established from the long bones of 3 Fischer D+ and D- rats as described. . .

with the WEHI- 1 64 fibrosarcoma demonstrated that PT- I 00 could suppress the growth of an established s.c. tumor. In addition, when PT- I 00 administration was started shortly after implantation of VVEHI- 1 64 on day 2, it was found that not. . .

CLMEN. . . of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1 . -1 As all required additional search fees were timely paid by the applicant, this International Search Report covers all F searchable claims.

2 As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3 As only some of the required additional search fees were timely paid by the applicant, this International Search Report F covers only those claims for which fees were. . .

4 F1 No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest E1The additional search fees were accompanied by the applicant's protest.

F-1 No protest accompanied the payment of additional search fees.

Form PCT/ISA/21 0 1continuation of first sheet (1) (July 1998)  
INTERNATIONAL SEARCH REPORT  
International Application No. PCTAis 00 /14505  
FURTHER INFORMATION CONTINUED. . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.13	3.34

STN INTERNATIONAL LOGOFF AT 16:11:39 ON 19 JUN 2006